

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

<i>COMPLETE IF KNOWN</i>	
Application Number	10/554,185
Filing Date	October 21, 2005
First Named Inventor	Mark T. Bilodeau
Group Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	21377YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/OO/	PCT	WO 97/08167 ✓			Smithkline Beecham Plc	03/06/1997
	PCT	WO 96/11929 ✓			Smithkline Beecham Plc.	04/25/1996
	PCT	WO 01/66525 ✓			Astrazeneca Ab.	09/13/2001
	PCT	WO 97/49704 ✓			Janssen Pharmaceutica Nv.	12/31/1997
	PCT	WO 97/22360 ✓			Medical Research Counsil	06/26/1997
	PCT	WO 01/91754 ✓			Peptor Ltd.	12/06/2001
	PCT	WO 96/23769 ✓			Smithkline Beecham PLC.	08/08/1996
	PCT	WO 02/083138 ✓			Merck & Co., Inc.	10/24/2002
	PCT	WO 03/084473 ✓			Merck & Co., Inc.	10/16/2003
/CC/	PCT	WO 94/10171 ✓			Pfizer Inc.	05/11/1994

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

SEND TO: Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 Copy as prepared from "IDS Form" (IDS Edition), March & Co., Inc., 7/12/2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

3

Attorney Docket Number

COMPLETE IF KNOWN

Application Number	10/554,185
Filing Date	October 21, 2005
First Named Inventor	Mark T. Bilodeau
Group Art Unit	To be determined
Examiner Name	To be determined
Attorney Docket Number	21377YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

/Celia Chang/

Date Considered

07/11/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				COMPLETE IF KNOWN	
				Application Number	10/554,185
				Filing Date	October 21, 2005
				First Named Inventor	Mark T. Bilodeau
				Group Art Unit	To be determined
				Examiner Name	To be determined
Sheet	3	of	3	Attorney Docket Number	21377YP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
/CC/	✓	Kunick, et al. Database Caplus on Stn, J. Medicinal Chemistry, Vol. 47(1), pp. 22-36, Abstract, 2004
/CC/		Barnett, et al. Database Calpus on Stn., Bioorganic & Medicinal Chemistry, Vol. 26(11), pp. 1221-1226, Abstract, 2004
/CC/	✓	DeFeo-Jones, et al. Molecular Cancer Therapeutics, Vol. 4(2), pg. 271-279 (2005)
/CC/	↓	Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, Vol. 15(3), pg. 761-764 (2005)

Examiner Signature	/Celia Chang/	Date Considered	07/11/2008
--------------------	---------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. -7/12/2005